The Power of Pharmacist Interventions in Improving Glycemic Control for Diabetes Patients: A Multicenter Study in Malaysia

By Staff Writer

July 10, 2023

A recent study conducted in Malaysia has shed light on the significant impact of pharmacist interventions on glycemic control in diabetic patients. The study, which focused on the Diabetes Medication Therapy Adherence Clinic (DMTAC) program, revealed a substantial reduction in HbA1c levels among patients after their visits to the clinic.

The findings of this study were consistent with previous smaller-scale studies conducted in a health clinic and a tertiary hospital in Malaysia. These studies also demonstrated a significant reduction in HbA1c levels among diabetic patients. Additionally, the study found that patients who did not default from follow-up visits achieved significantly lower HbA1c levels compared to those who did default.

Several factors were identified as independent predictors of HbA1c levels, including the frequency of DMTAC visits, duration of diabetes, number of dosage adjustments, and the use of antidiabetic agents. The study also highlighted the overall improvement in HbA1c levels among all subjects, including the defaulters, from baseline until post-2 (up to a year).

The study emphasized the need for adherence to follow-up schedules in diabetes clinics, as patients who adhered to DMTAC follow-up experienced a greater reduction in HbA1c levels. It also highlighted the potential benefits of a more holistic and multidisciplinary approach to treating diabetic patients, such as combining different clinics and reducing the number of follow-ups.

While there was no significant difference in glycemic control between patients who visited DMTAC in hospitals and primary health clinics, a higher default rate was observed in hospital patients. This suggests the need to strengthen primary health care and optimize its utilization among diabetes patients.

The study also analyzed the predictors that led to HbA1c reduction and found that more frequent DMTAC visits during the initial phase had a positive impact on glycemic control. However, this impact was not observed in the second phase of follow-up. Optimization of diabetic treatment, particularly through pharmacist-led interventions such as dosage adjustment and the addition of antidiabetic agents, significantly improved glycemic control in the longer term.

This real-world study provides valuable insights into the factors and interventions associated with improved glycemic control in diabetes patients. It highlights the crucial role of pharmacists in diabetes care and offers guidance to policymakers in determining key performance indicators in DMTAC.

Reference url

Recent Posts

lenacapavir HIV PrEP access
    

Global Health Partnerships Unite to Expand Access to Lenacapavir for HIV Prevention

💉 How can we ensure equitable access to HIV prevention methods like lenacapavir?

A recent initiative from the Global Fund, supported by key global health organizations, aims to provide affordable access to this new HIV pre-exposure prophylaxis medication.

With a goal to reach 2 million individuals over three years, this coordinated effort seeks to drastically cut HIV infections and align with our commitment to ending AIDS by 2030.

Explore the details of this impactful collaboration and how it could transform HIV prevention.

#SyenzaNews #globalhealth #HealthcareInnovation #MarketAccess

antimicrobial resistance africa
     

Africa’s Health Crisis: Antimicrobial Resistance and Mpox Outbreak

🌍 Are we prepared to tackle the hidden pandemic of antimicrobial resistance (AMR) in Africa?

With AMR rapidly becoming a dominant health crisis, it’s critical to understand its impact on our healthcare systems and most vulnerable populations.

The Africa CDC highlights the urgent need for substantial investment and coordinated responses to combat this escalating threat, alongside the ongoing Mpox outbreak.

Discover the pressing challenges and potential solutions in our latest article.

#SyenzaNews #GlobalHealth #HealthcareInnovation #AntimicrobialResistance #PublicHealth

BioSapien cancer drug delivery
    

BioSapien Innovative Cancer Drug Delivery Solutions

🌟 How is innovation in drug delivery shaping the future of cancer treatment? 🌟

Discover how UAE-based BioSapien is transforming the healthcare landscape with the MediChip™ platform, securing $5.5 million in pre-Series A funding to enhance cancer care.

This innovative solution promises to minimise side effects and improve treatment outcomes for patients, fully embracing the potential of biotechnology in the fight against cancer.

Read more about BioSapien’s journey and its impact on global health!

#SyenzaNews #biotechnology #oncology #innovation #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.